

Beroni Group announces appointment of Dr. John Chiplin to Board of Directors

01 April 2022 | News

Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries



Beroni Group, an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, has appointed Dr. John Chiplin as an independent director to Beroni's Board of Directors effective April 1, 2022. Dr. Chiplin is an accomplished biotech executive and investor with a proven track record of building successful biotech companies.

Dr. John Chiplin, is Managing Director of Newstar Ventures Ltd. and Chairman of the Board of Biotherapy Services, N4 Pharma plc and Scancell Holdings plc. Dr. Chiplin has significant operational, investment and international experience in the life science and technology industries. From 2014 to 2016, he served as executive director of Benitec Biopharma Inc. and helped executed the company's US IPO. From 2012 to 2014, he was President and Chief Executive Officer of Polynoma, a Phase III cancer vaccine company, and from 2006 to 2009 he was Chief Executive Officer of Arana Therapeutics. Prior to this, Dr. Chiplin was head of the ITI Life Sciences investment fund in the UK, where he managed significant negotiations regarding funding with Government Ministers. He had been influential in various other transactions including Intrexon's acquisition of Medistem, Cephalon's acquisition of Arana Therapeutics, and GlaxoSmithKline's acquisition of Domantis. He also serves on several boards including Kings Arms Yard VCT plc and US private company Batu Biologics. Dr. Chiplin received his doctorate degree in Pharmaceutical Science from The University of Nottingham, U.K.